Dr Tom Weaver is the CEO of Congenica, a spin-out from the Wellcome Trust Sanger Institute. The company is a world leading developer of genome-based discovery and diagnostic technologies.
Tom holds a PhD in Experimental Oncology and has a proven track record of creating value in highly successful start-up companies, applying genome-based technologies and contract services for fundamental research, clinical, and drug discovery purposes.
He has also led large infrastructure programs in genomics and animal model genetics, serving as a Director at the Medical Research Council (Oxford, UK). He trained at the University of Cambridge and MRC Lab for Molecular Biology (Cambridge, UK).